Intensive care treatment of patients with hypertension: Report of three cases
DOI:
https://doi.org/10.52076/eacad-v3i3.295Keywords:
Intensive care; Aggravation; Comorbidity.Abstract
The impact of clinical hypertension, however, is pointed out as a major predisposition to worsening, in with COVID-19 in this interaction still insufficiently investigated. The coronavirus disease 2019 (COVID-19) has become a worldwide responsible for a worldwide pandemic of deaths. Common hypertension has been identified as one of the comorbidities and risk factors for severity and adverse consequences. Recent investigations raise the question of hypertension a predictor of patients with COVID-19 independently of others such as chronic diseases, obesity, other cardiovascular diseases, kidney, liver and lung diseases. The purpose of this report was to provide a clinical view of hypertension in intensive care with or without the effect of blood pressure levels, the impact of previously known hypertension and the effect of antihypertensive therapy on severity and outcomes in patients with and without COVID-19.
References
Barroso, W. K. S., Rodrigues, C. I. S., Bortolotto, L. A., Mota-Gomes, M. A. & Brandão, A. A. (2021). Diretrizes Brasileiras de Hipertensão Arterial. Arq Bras Cardiol. 116(3):516-658.
Caldeira, D., Alves, M., Melo, R.G., António, P.S. Cunha N, Nunes-Ferreira A, et al. (2020). Angiotensinconverting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: systematic review and meta-analysis. Int J Cardiol Heart Vasc.,31:100627.
Chan, J.F. (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating personto-person transmission: a study of a family cluster. Lancet. Cell. 2020,181(2):271-280.e8.
Coelho, J., Guimarães, M., Campos, L. C., & Flórido, C. F. (2021). Blood pressure control of hypertensive patients followed in a high complexity clinic and associated variables. Orgão oficial de Sociedades Brasileira e Latino-Americana de Nefrologia, 43(9859).
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., & Erichsen, S. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181(2):271-280.e8.
Howard, J. T., Sosnov, J. A., Janak, J. C., Gunlapalli, A. V., Pettey, W. B., & Walker, L. E. (2018). Associations of initial injury severity and posttraumatic stress disorder diagnoses with long-term hypertension risk after combat injury. Hypertension.71:824–32.
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., & Hu, Y. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 395(10223):497-506.
Keasley, J., Oyebode, O., Shantikumar, S., Proto, W., McGranahan, M., Sabouni, A., & Kidy, F. (2020). A systematic review of the burden of hypertension, access to services and patient views of hypertension in humanitarian crisis settings. BMJ Glob Health.5(11): e002440.
Larkin, K. T., & Cavanagh, C. (2016). Hypertension. West Virginia University, Morgantown, WV, USA. Encyclopedia of Mental Health. Volume 2. Elsevier Inc. All rights reserved.
Ministério da Saúde (2020). Protocolo de Tratamento do Novo Coronavírus. Brasilia-DF, Ver. 1.
Ministério da Saúde / SAPS (2022). Protocolo de manejo clínico do coronavírus (covid-19) na atenção primária à saúde. Brasilia-DF, Versão 7.
Nägele, M. P., Haubner, B., Tanner, F. C., Ruschitzka, F., & Flammer, A. J. (2020) Endothelial dysfunction in COVID-19: current findings and therapeutic implications. Atherosclerosis. 314:58-62.
Pinheiro, I. M., Montes, S. S., Fraga, H. C. J. R., Souza, R. S., Pinheiro, I. M., Machado, A. O., Lima, S. B. P., Coelho, J. M. F., Macedo, M. C., Souza, E. R., Saba, H., Jorge, E. M. F., Sampaio, R. L., Batista, W. O., Araujo, M. L., Benevides, C. M. & Souza, A. C. S. S. (2020). Systemic arterial hypertension: treatment with Integrative and Complementary Health Practices Research. Society and Development, 9(11), e45991110156.
Ran, J., Song, Y., Zhuang, Z., Han, L., Zhao, S., & Cao, P. (2020). Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China. Hypertens Res. 43(11):1267-76.
Ribeiro, A.C., & Uehara, A.S.C.S (2022). Systemic arterial hypertension as a risk factor for the severe form of covid-19: scoping review. Rev Saude Publica. 56:20.
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., & McGinn, T. (2020). The Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 323(20):2052-2059.
Scientific Brief. COVID-19 and hypertension. Scientific Brief. Geneva: World Health Organization, June 2021.
Sprint, R. G., Wright, J. J. T., Williamson, J. D., Whelton, P. K., Snyder, J. K., & Sink, K. M. (2015). A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 373(22):2103-16.
Tadic, M., Saeed, S., Grassi, G., Taddei, S., Mancia, G., & Cuspidi, C (2021). Hypertension and COVID-19: ongoing controversies. Front Cardiovasc Med.8:639222.
Toledo, J.C.Y. (2020). Posicionamento Brasileiro sobre Hipertensão Arterial Resistente. Arq. Bras. Cardiol. 114(3), 576 - 596.
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020). Reninangiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 382(17):1653-1659.
Wang, C. (2020). A novel coronavirus outbreak of global health concern. Lancet. Cell. 181(2):271-280.e8.
Wei, Z. Y., Qiao, R., Chen, J., Huang, J., Wu, H., & Wang, W. J. (2021). The influence of pre-existing hypertension on coronavirus disease 2019 patients. Epidemiol Infect. 149:e4.
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., Palma, S. M., Gidding, S., Jamerson, K. A., & Jones, D. W. (2018). Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension.71:1269–1324.
WHO - World Health Organization (2020). COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers. Scientific Brief. Geneva: World Health Organization.
WHO Interim guidance (2020). Home care for patients with suspected novel coronavirus (nCoV) infection presenting with mild symptoms and management of contacts. Cell. 181(2):271-280.e8.
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D.L., Coca, A., Simone, G., & Dominiczak, A. (2018). The Task Force for the Management Of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. Crossref. PubMed. 36:1953–2041.
Xie, J., Tong, Z., Guan, X., Du, B., & Qiu, H. (2020). Clinical characteristics of patients who died of coronavirus disease 2019 in China. JAMA Netw Open. 3(4):e205619.
Yugar-Toledo, J. C., Yugar, L. B. T., Tácito, L. H. B., & Vilela-Martin, J. F. (2021). Disfunção endotelial e hipertensão arterial. Rev Bras Hipertens. 28,22(3):84-92.
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., & Liu, Z. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 395(10229):1054-62.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Luana Teles de Sá Maia; Themis Borche da Silva; Andrezza Maria de Oliveira; Amanda Cavalcante de Albuquerque; Silvecler Cortijo de Campos; Luiz Carlos Ufei Hassegawa; Ennely Mendonça Gutzeit; Daniel Kucharski Frari; Iara Vaz Lopes; Saraí Vieira Ferraz; Tainã Dalila Santos Rodrigues; Thiago Vaz Lopes; Yan Ohana Oliveira Costa
This work is licensed under a Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
1) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
2) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
3) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado.
